The Latest Cardiac and Vascular News
First Quarter 2022 Highlights Revenue was $304 million; GAAP net income per diluted share was $0.81; and Non-GAAP net income per diluted share was $0.93. IRVINE, Calif.–(BUSINESS WIRE)–Masimo (Nasdaq: MASI) today announced its financial results for the first quarter of 2022, ended April 2, 2022. First Quarter 2022 Results Revenue […]
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. Total revenue in the first quarter of 2022 grew 22% year-over-year to $461.9 million, compared to $379.1 million in the first […]
Dr. Lynne Nowak Joins Lark as Chief Medical Officer and Shannon Marques Joins as Senior Vice President of Revenue Operations MOUNTAIN VIEW, Calif., May 3, 2022 /PRNewswire/ — Lark Health today announced it has appointed Lynne Nowak, MD, as Chief Medical Officer and Shannon Marques as Senior Vice President of Revenue Operations. Dr. Nowak and Marques are […]
Expansion of board signals digital health company’s growth and increased focus on creating access to cardiac ultrasound TEL AVIV, Israel, May 3, 2022 /PRNewswire/ — UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power of artificial intelligence, is proud to announce that Ruth Atherton, PhD, JD, has joined its board of […]
2022 Q1 HIGHLIGHTS compared to the corresponding period of 2021: Revenues were $14.0 million, an increase of $0.8 million, or 6%, compared to $13.2 million Net income was $3.4 million, or $0.50 per basic share and $0.41 per diluted share, compared to $4.9 million, or $0.73 per basic share and $0.60 per diluted share Cash at March 31, 2022 increased to $38.4 million from $26.5 million SANTA CLARA, Calif., May […]
– Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation– – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew approximately 109% Y/Y to $13.4 Million in the First Quarter 2022– – Retail Prescription Equivalents Grew 56.7% Year over Year – ANN ARBOR, Mich., May […]
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first […]
First-Quarter 2022 Revenues of $25.7 Billion, Reflecting 82% Operational Growth; Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Increased 2% Operationally First-Quarter 2022 Reported Diluted EPS(2) of $1.37 and Adjusted Diluted EPS(3) of $1.62 Both Reported(2) and Adjusted(3) Diluted EPS Include a $0.05 Negative Impact for Acquired In-Process R&D Expenses(4), Which Prior to First-Quarter 2022 Had […]
New investment will progress treatment of pulmonary arterial hypertension (PAH), a rare condition which causes high blood pressure in the blood vessels that supply the lungs and can lead to heart failure. Current approved medications mainly address the symptoms of this rare condition. This novel approach aims to address the […]
The Financing round was led by growth equity firm Stripes, and marks Hello Heart’s leadership in cardiovascular digital therapeutics and proven ability to close gaps in heart health – the number one cause of death in the U.S. MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses on […]
